SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase 1/2 results.
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
August 31, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022